Mergers & Acquisitions
Greenhill's M&A practice includes some of the most experienced professionals in the industry. Drawing on that experience, we are active across the full range of M&A advisory roles:
Sell-side Advisory
Leveraging our network of experienced Managing Directors, we have a strong track record in sell side advisory roles. Acting for target companies, special board committees or selling shareholders, we can operate at the heart of any process, assist in negotiations and provide incisive and deeply informed advice about the merits of bids received.
Buy-side Advisory
We have a strong record of successful buy side advisory assignments in relation to public or private target companies and are able to advise interested buyers on attractive targets through our global network of relationships.
Merger Advisory
Greenhill is well qualified to assist clients on merger transactions given the long experience of its partners and professionals, an assurance of total discretion. Greenhill has a number of sizeable mergers in its list of completed transactions both in the US and internationally.
Special Advisory
Various advisory work that we undertake does not fit a conventional ‘transaction’ definition. Examples include our work advising the Australian National Rugby League Commission on the sale of television broadcast rights and work for the global partnership of Arthur Andersen in the immediate aftermath of the cases that followed the collapse of Enron. We believe that Greenhill’s experience, expertise and discretion positions us well for special advisory assignments.
Cross-border Advisory
Greenhill’s network of international offices allow us to offer clients a seamless cross-border advisory service with a truly global perspective.
Recent Transactions
Sort By

Coca-Cola Enterprises Inc.

Advised the Affiliated Transaction Committee of Coca-Cola Enterprises Inc. on the sale of its North American bottling operations to The Coca-Cola Company and on its concurrent acquisition of The Coca-Cola Company’s bottling operations in the Nordic region

Novartis AG’s 36.5% stake in Consumer Health Joint Venture

Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture

Alcon, Inc.

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

Blue Owl Technology Finance Corp. II (“OTF II”)

Advised and provided a fairness opinion to the Special Committee of the Independent Directors of OTF II, a specialty finance company focused on originating and making loans to, and making debt and equity investment in, technology related companies, specifically software, based primarily in the US, on its merger with OTF

Kelda Group plc

Advised Kelda Group plc, a leading provider of water and waste water services in the UK, on a recommended cash offer from a consortium of international infrastructure investors